A Phase 1/2 Clinical Trial of Enzyme Replacement in Fabry Disease: Pharmacokinetic, Substrate Clearance, and Safety Studies
- 1 March 2001
- journal article
- clinical trial
- Published by Elsevier BV in American Journal of Human Genetics
- Vol. 68 (3), 711-722
- https://doi.org/10.1086/318809
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Quantitative Determination of Globotriaosylceramide by Immunodetection of Glycolipid-Bound Recombinant Verotoxin B SubunitAnalytical Biochemistry, 1999
- Enzyme therapy for Gaucher disease: the first 5 yearsBlood Reviews, 1998
- Human -galactosidase A: characterization of the N-linked oligosaccharides on the intracellular and secreted glycoforms overexpressed by Chinese hamster ovary cellsGlycobiology, 1998
- Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease.1993
- Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion.The Journal of cell biology, 1992
- An Atypical Variant of Fabry's Disease with Manifestations Confined to the MyocardiumNew England Journal of Medicine, 1991
- Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's diseaseVirchows Archiv, 1990
- The short-form McGill pain questionnairePain, 1987
- Enzyme therapy XVII: metabolic and immunologic evaluation of alpha- galactosidase A replacement in Fabry disease.1980
- Replacement Therapy for Inherited Enzyme DeficiencyNew England Journal of Medicine, 1973